ReviewPharmacoEconomics2019

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Tosin Lambe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.